NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (Amex: PRW), a company “Advancing Drugs Through Glycoscience®”, today reported it has submitted a plan to the American Stock Exchange (Amex) on July 23rd that outlines the Company’s plan to regain compliance with Amex’s continued listing requirements. The Amex has not provided the Company with a timetable for its formal response to the submitted plan and the plan’s acceptance is at the discretion of the Amex. If the plan is accepted, the Company may be able to continue its listing during the plan period of up to 18 months during which time it will be subject to periodic review to determine whether it is making progress consistent with the plan. Failure to make progress or to regain compliance with the continued listing standards could result in the Company being de-listed from the Amex.
